All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or Myeloma crowd.
During the 8th World Congress on Controversies in Multiple Myeloma (COMy), the Multiple Myeloma Hub was pleased to speak to María-Victoria Mateos, University Hospital of Salamanca, Salamanca, ES. We asked, What are the current and future strategies for maintenance therapy after autologous transplant?
What are the current and future strategies for maintenance therapy after autologous transplant?
Mateos begins by discussing the aims of maintenance therapy and outlines the current standard of care (lenalidomide), in addition to newer therapies such as proteasome inhibitors and monoclonal antibodies. Finally, Mateos discusses the importance of determining the optimal duration of therapy.
What are the key considerations of the updated guidelines for early relapsed multiple myeloma?
The Multiple Myeloma Hub was pleased to speak to Shaji Kumar, Mayo Clinic, Rochester, US. We asked, What are the key considerations of the updated...
Key considerations when treating patients with newly diagnosed high-risk MM
During the 2021 ASCO Annual Meeting, the Multiple Myeloma Hub spoke with Saad Zafar Usmani, Levine Cancer Institute, Charlotte, US. He discussed key considerations when...
Subscribe to get the best content related to multiple myeloma delivered to your inbox